PhotoPharmics https://photopharmics.com/ A New Therapy for Neurodegenerative Diseases Fri, 28 Feb 2025 20:11:55 +0000 en-US hourly 1 https://wordpress.org/?v=6.7.2 https://photopharmics.com/wp-content/uploads/2017/04/cropped-icon-32x32.png PhotoPharmics https://photopharmics.com/ 32 32 Available Diagnosis and Treatment for Parkinson’s https://photopharmics.com/available-diagnosis-and-treatment-for-parkinsons/ Fri, 28 Feb 2025 20:11:55 +0000 https://photopharmics.com/?p=5872 Introduction Parkinson’s is one of the most common neurodegenerative disorders, second only to Alzheimer’s. Globally, it affects around 1% of people over 60, making it the leading movement-related neurological condition. “Parkinson’s diagnosis and treatment options” is one of the most common concerns for individuals living with Parkinson’s and their families. The uncertainty surrounding symptoms, medical […]

The post Available Diagnosis and Treatment for Parkinson’s appeared first on PhotoPharmics.

]]> PhotoPharmics Announces Leadership Transition in Clinical & Scientific Advisory Board https://photopharmics.com/photopharmics-announces-leadership-transition-in-clinical-scientific-advisory-board/ Fri, 31 Jan 2025 17:00:00 +0000 https://photopharmics.com/?p=5846 PhotoPharmics, a pioneer in specialized phototherapy for neurodegenerative diseases, today announced the appointment of Robert A. Hauser, MD, MBA, as the new Chairman of its Clinical & Scientific Advisory Board (CSAB). Dr. Hauser assumes this leadership role following the recent passing of Warren Olanow, MD, FRCPC, a visionary in the field of Parkinson’s disease research […]

The post PhotoPharmics Announces Leadership Transition in Clinical & Scientific Advisory Board appeared first on PhotoPharmics.

]]> Understanding the Types of Parkinsonism https://photopharmics.com/understanding-the-types-of-parkinsonism/ Mon, 27 Jan 2025 18:54:09 +0000 https://photopharmics.com/?p=5809 This article explains Parkinsonism, a group of conditions mimicking Parkinson's disease, detailing its various types, including primary (like PD and atypical forms) and secondary causes. It also discusses diagnosis, the importance of neurological evaluation, and emerging therapies for managing symptoms.

The post Understanding the Types of Parkinsonism appeared first on PhotoPharmics.

]]> Parkinson’s Iceberg: The Non-Motor Symptoms You Don’t See https://photopharmics.com/non-motor-symptoms-of-parkinsons/ Fri, 20 Dec 2024 16:39:19 +0000 https://photopharmics.com/?p=5786 Introduction “My father experienced hallucinations and delusions, and at the time, we didn’t realize these symptoms were part of his Parkinson’s disease. My mom tried to shield my family and carry the burden alone each day. I wish l’d known there was more to Parkinson’s than motor symptoms, which is why l’m encouraging people and […]

The post Parkinson’s Iceberg: The Non-Motor Symptoms You Don’t See appeared first on PhotoPharmics.

]]> An Overview of Parkinson’s Disease https://photopharmics.com/an-overview-of-parkinsons-disease/ Thu, 05 Dec 2024 18:52:43 +0000 https://photopharmics.com/?p=5751 What is Parkinson’s? Parkinson’s Disease (PD) is a complex neurodegenerative disorder that affects the nervous system and progressively worsens over time.  While motor symptoms—such as tremors, stiffness, and slow movement—are often the most observable and commonly associated with the condition, Parkinson’s encompasses a broader spectrum of challenges.  Non-motor symptoms (NMS), including anxiety, depression, apathy, and […]

The post An Overview of Parkinson’s Disease appeared first on PhotoPharmics.

]]> PhotoPharmics to Present Patient Interest Findings from Groundbreaking Remote Parkinson’s Trial at PSG Annual Meeting https://photopharmics.com/photopharmics-to-present-patient-interest-findings-from-groundbreaking-remote-parkinsons-trial-at-psg-annual-meeting/ Thu, 05 Dec 2024 16:00:25 +0000 https://photopharmics.com/?p=5769 Presentation to Highlight Feasibility and Interest in Decentralized Home-Based Phase 3 Trial Salt Lake City, Utah — December 5, 2024 — PhotoPharmics, a pioneer in non-invasive phototherapy for neurological disorders, today announced it will present a poster titled “An Entirely Remote, Home-based Phase 3 Clinical Trial of a Specialized Light Therapy Device for Parkinson’s Disease […]

The post PhotoPharmics to Present Patient Interest Findings from Groundbreaking Remote Parkinson’s Trial at PSG Annual Meeting appeared first on PhotoPharmics.

]]> PhotoPharmics Announces First Subject Completes FDA Pivotal Clinical Trial for the Celeste Device in Parkinson’s https://photopharmics.com/photopharmics-announces-first-subject-completes-fda-pivotal-clinical-trial-for-the-celeste-device-in-parkinsons/ Sun, 29 Sep 2024 12:18:51 +0000 https://photopharmics.com/?p=5713 PhotoPharmics, a leader in non-invasive phototherapy for neurological disorders, has reached a significant milestone in its ongoing FDA pivotal “Light for PD” trial for the Celeste therapeutic device. The first subject has successfully completed the full 6-month treatment course and clinical visits, marking an important step towards the successful completion of the trial and future FDA authorization of Celeste in treating Parkinson’s disease (PD).

The post PhotoPharmics Announces First Subject Completes FDA Pivotal Clinical Trial for the Celeste Device in Parkinson’s appeared first on PhotoPharmics.

]]> PhotoPharmics Welcomes Three Renowned Experts to Its Clinical & Scientific Advisory Board https://photopharmics.com/photopharmics-welcomes-three-renowned-experts-to-its-clinical-scientific-advisory-board/ Thu, 12 Sep 2024 14:58:25 +0000 https://photopharmics.com/?p=5672 PhotoPharmics, an innovator in light-based therapies for neurodegenerative diseases, proudly announces the appointment of three eminent experts to its Clinical & Scientific Advisory Board (CSAB). The new members—Dr. Charles H. Adler, Dr. George Brainard, and Dr. Robert A. Hauser—bring unparalleled expertise to the advisory board, reinforcing PhotoPharmics' mission to pioneer groundbreaking treatments for Parkinson’s disease and other neurodegenerative disorders.

The post PhotoPharmics Welcomes Three Renowned Experts to Its Clinical & Scientific Advisory Board appeared first on PhotoPharmics.

]]> PhotoPharmics Enrolls First 100 Participants in Groundbreaking Parkinson’s Disease Trial https://photopharmics.com/photopharmics-enrolls-first-100-participants-in-groundbreaking-parkinsons-disease-trial/ Thu, 08 Aug 2024 16:00:10 +0000 https://photopharmics.com/?p=5661 PhotoPharmics, a leader in neurodegenerative disease phototherapy, today announced the enrollment of the first 100 subjects in its Light for PD clinical trial. This marks a significant milestone in evaluating Celeste, the company’s FDA Breakthrough light therapy device for Parkinson's disease (PD). Organizers are on track to enroll 300 subjects—interested individuals with PD may find details at lightforpd.com.

The Light for PD trial is a randomized, double-blind, placebo-controlled study that aims to demonstrate safety and significant improvement in motor and non-motor symptoms beyond current medical care in PD.  Parkinson’s disease happens when the brain can no longer regulate essential signaling for movement and other function. Recent discoveries implicate the eyes as part of this signaling process. Celeste passively delivers specific wavelengths of light aimed to restore retinal signaling, improving function and quality of life for those living with PD.

The post PhotoPharmics Enrolls First 100 Participants in Groundbreaking Parkinson’s Disease Trial appeared first on PhotoPharmics.

]]> PhotoPharmics Enrolls First 25 Patients in Pivotal Parkinson’s Disease Study to Improve Symptoms Beyond the Current Standard of Care https://photopharmics.com/photopharmics-enrolls-first-25-patients-in-pivotal-parkinsons-disease-study-to-improve-symptoms-beyond-the-current-standard-of-care/ Mon, 13 May 2024 14:00:04 +0000 https://photopharmics.com/?p=5632 PhotoPharmics, the leader in specialized phototherapy for neurodegenerative diseases, today announced the successful enrollment of its first 25 patients into the Celeste Light for PD Trial. This groundbreaking trial represents a significant advancement in Parkinson's disease (PD) treatment, where motor treatments become less effective over time, and no FDA approved treatments exist for many debilitating non-motor symptoms.

The post PhotoPharmics Enrolls First 25 Patients in Pivotal Parkinson’s Disease Study to Improve Symptoms Beyond the Current Standard of Care appeared first on PhotoPharmics.

]]>